Prognostic Study of Via Dynamic Change of dT-DNA in Drainage Fluid After Radical Prostatectomy

Launched by SHANGHAI GENERAL HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Nov 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how changes in a specific type of DNA, called drainage tumor DNA (dT-DNA), found in the fluid that drains from the surgical site after prostate surgery, can help predict outcomes for patients with prostate cancer. Prostate cancer is a common illness in men, and a radical prostatectomy is a surgery often used to treat it. While doctors currently use blood tests measuring PSA levels to monitor prostate cancer, this study aims to see if analyzing dT-DNA levels can offer better insights into how patients are doing after their surgery and help tailor future treatments.

To participate in this study, patients need to be men diagnosed with prostate cancer who have undergone a radical prostatectomy. However, those who received certain treatments before surgery or experienced urine leakage after surgery may not be eligible. While the trial is not yet recruiting participants, it is designed to provide important information that could improve how doctors monitor and treat prostate cancer after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Prostate cancer patients treated with radical prostatectomy
• Exclusion Criteria:
• • 1. Received neoadjuvant endocrine/chemotherapy before surgery;
• • 2. Urine leakage after surgery (positive creatinine test of drainage fluid).